ReviewInfectious agents and cancer2026
Prognostic significance of quantitative EBV biomarkers in extranodal NK/T-cell lymphoma: a meta-analysis of EBV DNA load and EBER-positive cell proportion.
Review in Infectious agents and cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesPre-treatment peripheral blood EBV DNA and tumor EBV-encoded small RNA (EBER) are recognized prognostic factors in Extranodal NK/T-Cell Lymphoma (ENKTL). However, their quantitative values and optimal positive thresholds remain inconsistent, hindering clinical application. This meta-analysis systematically assesses their prognostic value in ENKTL.
methodsRelevant studies from PubMed, Embase, Web of Science, and Cochrane Library were searched until 24 December, 2025. Eligible studies reported hazard ratios (HRs) for overall survival (OS) based on Pre-treatment EBV DNA levels or tumor EBER positivity. Subsequently, Pooled HRs with 95% confidence intervals (CIs) were calculated via random-effects models. Next, Subgroup analyses examined different blood compartments, EBV DNA cut-offs, and study design. Additionally, Heterogeneity (I²) and publication bias (Egger’s test) were assessed.
resultsIn total, 17 studies from 15 articles were enrolled in this meta-analysis, including 15 on EBV DNA and 2 on EBER. These studies demonstrated that elevated pre-treatment EBV DNA level (HR = 3.04, 95% CI 1.97–4.69; P < 0.001, I2 = 38%) and high tumor EBER positivity thresholds of ≥ 75% (HR = 5.53, 95%CI2.21-14.38; P < 0.001, I2 = 0%) independently predicted reduced survival. Moreover, Stratification by EBV DNA cut-off (500 copies/ML) showed significantly higher mortality risk in the ≥ 500 group (HR = 2.82, 95% CI 1.84–4.31; P < 0.001) compared to the < 500 group (HR = 2.66, 95% CI 0.56–12.72; P = 0.22). Furthermore, Egger’s test suggested no publication bias(P = 0.111). Finally, Sensitivity analyses suggested the robustness and credibility of our results.
conclusionsHigh pre-treatment EBV DNA load (cut-off of ≥ 500 copies/mL) and high EBER-Positive Cell Proportion (≥ 75%) predict poor survival in ENKTL. Those quantitative EBV Biomarkers may serve as practical biomarkers for risk stratification and guiding therapeutic decisions in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.